Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Publication Digest: Time to publication of cost-effectiveness analyses for medical devices

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Everhart investigated the availability of cost-effectiveness analyses (CEAs) for medical devices in the United States. By analyzing data from the Tufts University Cost-Effectiveness Analysis Registry, the author identified 218 CEAs published between 2002 and 2020. On average, these CEAs were published 4 to 6 years after FDA approval or clearance of the studied devices. The findings suggest that decision-makers often lack timely evidence of cost-effectiveness when making initial reimbursement decisions regarding newly available medical devices.

Access the full-text article here.